Nonexclusive agreement includes human and viral miRNAs.
Rosetta Genomics nonexclusively licensed Rockefeller University’s viral and human miRNAs genes for research applications. Previous agreements between the parties included therapeutic and diagnostic uses of the University’s miRNAs.
Rosetta Genomics’ says that its existing intellectual property estate includes two issued patents, two allowed patent applications, and 60 pending patent applications. The company reports that it has exclusive access to the majority of known miRNA genes through internal research as well as discoveries by The Johns Hopkins University School of Medicine, which are exclusively licensed to the firm.